Scancell’s second platform, Moditope®, is a completely novel concept based on stress-induced post translational modifications (siPTMs). The technology exploits and harnesses the normal immune response that utilises cytotoxic CD4 T cells to eradicate stressed cells. Tumour cells are, by nature, stressed due to their rapid growth and lack of oxygen and nutrients. By identifying these stress-induced modifications, Scancell has been able to design modified peptide vaccines which induce potent T cells that seek and destroy tumour cells.
The Moditope® platform also provides a pathway for the potential development of CD4-based T cell receptor (TCR) therapies, whereby T cells recognising siPTMs could be utilised for adoptive cell transfer. With most of the current approaches focused on CD8-based TCRs, the ability to isolate CD4-TCRs recognising these novel cancer targets opens up a new window of opportunity for Scancell’s Moditope® technology.